Common predisposition alleles for moderately common cancers: Bladder cancer

Current Opinion in Genetics and Development

Volumn 20, Issue 3, 2010, Pages 218-224

  Kiltie, Anne E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENE PRODUCT; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN TP63; UNCLASSIFIED DRUG; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ALLELE; BLADDER CANCER; BLADDER CARCINOGENESIS; DNA REPAIR; ETHNIC GROUP; EUROPE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; BLADDER TUMOR; GENETICS; GENOTYPE; PROCEDURES;

ALLELES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MYC; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 77953619147     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.01.002     Document Type: Review

References (43)

1. Manolio T.A., Collins F.S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 2009, 60:443-456.
2. Aben K.K., Witjes J.A., Schoenberg M.P., Hulsbergen-van de Kaa C., Verbeek A.L., Kiemeney L.A. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002, 98:274-278.
3. Murta-Nascimento C., Silverman D.T., Kogevinas M., Garcia-Closas M., Rothman N., Tardon A., Garcia-Closas R., Serra C., Carrato A., Villanueva C., et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?. Cancer Epidemiol Biomarkers Prev 2007, 16:1595-1600.
4. Aben K.K., Baglietto L., Baffoe-Bonnie A., Coebergh J.W., Bailey-Wilson J.E., Trink B., Verbeek A.L., Schoenberg M.P., Alfred Witjes J., Kiemeney L.A. Segregation analysis of urothelial cell carcinoma. Eur J Cancer 2006, 42:1428-1433.
5. Garcia-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D.W., Tardon A., Serra C., Carrato A., Garcia-Closas R., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005, 366:649-659.
6. Kiltie A.E. Molecular epidemiology of DNA repair genes in bladder cancer. Methods Mol Biol 2009, 472:281-306.
7. Kiemeney L.A., Thorlacius S., Sulem P., Geller F., Aben K.K., Stacey S.N., Gudmundsson J., Jakobsdottir M., Bergthorsson J.T., Sigurdsson A., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008, 40:1307-1312.
8. Wu X., Ye Y., Kiemeney L.A., Sulem P., Rafnar T., Matullo G., Seminara D., Yoshida T., Saeki N., Andrew A.S., et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009, 41:991-995.
9. Ioannidis J.P., Thomas G., Daly M.J. Validating, augmenting and refining genome-wide association signals. Nat Rev Genet 2009, 10:318-329.
10. The International HapMap Consortium A haplotype map of the human genome. Nature 2005, 437:1299-1320.
11. Frazer K.A., Ballinger D.G., Cox D.R., Hinds D.A., Stuve L.L., Gibbs R.A., Belmont J.W., Boudreau A., Hardenbol P., Leal S.M., et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
12. Birney E., Stamatoyannopoulos J.A., Dutta A., Guigo R., Gingeras T.R., Margulies E.H., Weng Z., Snyder M., Dermitzakis E.T., Thurman R.E., et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816.
13. Visel A., Rubin E.M., Pennacchio L.A. Genomic views of distant-acting enhancers. Nature 2009, 461:199-205.
14. Amara N., Palapattu G.S., Schrage M., Gu Z., Thomas G.V., Dorey F., Said J., Reiter R.E. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001, 61:4660-4665.
15. Elsamman E., Fukumori T., Kasai T., Nakatsuji H., Nishitani M.A., Toida K., Ali N., Kanayama H.O. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int 2006, 97:1202-1207.
16. Sakamoto H., Yoshimura K., Saeki N., Katai H., Shimoda T., Matsuno Y., Saito D., Sugimura H., Tanioka F., Kato S., et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008, 40:730-740.
17. Wang M., Zhang W., Yuan L., Fu G., Wei Q., Zhang Z. Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis 2009, 30:991-996.
18. Kiemeney L.A., Grotenhuis A.J., Vermeulen S.H., Wu X. Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol 2009, 19:540-546.
19. Golka K., Hermes M., Selinski S., Blaszkewicz M., Bolt H.M., Roth G., Dietrich H., Prager H.M., Ickstadt K., Hengstler J.G. Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure. Pharmacogenet Genomics 2009.
20. Rafnar T., Sulem P., Stacey S.N., Geller F., Gudmundsson J., Sigurdsson A., Jakobsdottir M., Helgadottir H., Thorlacius S., Aben K.K., et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009, 41:221-227.
21. Stern M.C., Lin J., Figueroa J.D., Kelsey K.T., Kiltie A.E., Yuan J.M., Matullo G., Fletcher T., Benhamou S., Taylor J.A., et al. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res 2009, 69:6857-6864.
22. Yang H., Dinney C.P., Ye Y., Zhu Y., Grossman H.B., Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008, 68:2530-2537.
23. Yang H., Gu J., Lin X., Grossman H.B., Ye Y., Dinney C.P., Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 2008, 14:2236-2244.
24. Andrew A.S., Gui J., Sanderson A.C., Mason R.A., Morlock E.V., Schned A.R., Kelsey K.T., Marsit C.J., Moore J.H., Karagas M.R. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet 2009, 125:527-539.
25. Michiels S., Laplanche A., Boulet T., Dessen P., Guillonneau B., Mejean A., Desgrandchamps F., Lathrop M., Sarasin A., Benhamou S. Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk. Carcinogenesis 2009, 30:763-768.
26. Castillejo A., Rothman N., Murta-Nascimento C., Malats N., Garcia-Closas M., Gomez-Martinez A., Lloreta J., Tardon A., Serra C., Garcia-Closas R., et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 2009, 124:608-613.
27. Figueroa J.D., Malats N., Garcia-Closas M., Real F.X., Silverman D., Kogevinas M., Chanock S., Welch R., Dosemeci M., Lan Q., et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008, 29:1955-1962.
28. Moore L.E., Pfeiffer R.M., Poscablo C., Real F.X., Kogevinas M., Silverman D., Garcia-Closas R., Chanock S., Tardon A., Serra C., et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol 2008, 9:359-366.
29. Moore J.H., Gilbert J.C., Tsai C.T., Chiang F.T., Holden T., Barney N., White B.C. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 2006, 241:252-261.
30. Horikawa Y., Gu J., Wu X. Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene-environmental interactions. Curr Opin Urol 2008, 18:493-498.
31. Andrew A.S., Karagas M.R., Nelson H.H., Guarrera S., Polidoro S., Gamberini S., Sacerdote C., Moore J.H., Kelsey K.T., Demidenko E., et al. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered 2008, 65:105-118.
32. Zhang H., Bonney G. Use of classification trees for association studies. Genet Epidemiol 2000, 19:323-332.
33. Manolio T.A., Brooks L.D., Collins F.S. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008, 118:1590-1605.
34. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
35. Bodmer W., Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008, 40:695-701.
36. Schork N.J., Murray S.S., Frazer K.A., Topol E.J. Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 2009, 19:212-219.
37. Armour J.A. Human genetics: sharp focus on the variable genome. Nature 2009, 461:735-736.
38. Frazer K.A., Murray S.S., Schork N.J., Topol E.J. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009, 10:241-251.
39. Thomas G., Jacobs K.B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., Chatterjee N., Welch R., Hutchinson A., et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008, 40:310-315.
40. Khoury M.J., Bertram L., Boffetta P., Butterworth A.S., Chanock S.J., Dolan S.M., Fortier I., Garcia-Closas M., Gwinn M., Higgins J.P., et al. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol 2009, 170:269-279.
41. Easton D.F., Eeles R.A. Genome-wide association studies in cancer. Hum Mol Genet 2008, 17:R109-115.
42. Wu X., Lin J., Grossman H.B., Huang M., Gu J., Etzel C.J., Amos C.I., Dinney C.P., Spitz M.R. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol 2007, 25:4974-4981.
43. Wu X., Ros M.M., Gu J., Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008, 102:1207-1215.